Drugs / Fluzone High-Dose
Fluzone High-Dose
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02566265 | Sep 2015 → Oct 2017 | Waldenstrom macroglobulinemia, influenza, monoclonal gammopathy of uncertain significance, plasma cell myeloma | Yale University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluzone High-Dose | “Fluzone® high- dose vaccine was FDA approved in 2009 for adults aged 65 and older” NCT02566265 ↗ |
| Known as | Fluzone | “Fluzone® high- dose vaccine was FDA approved in 2009 for adults aged 65 and older” NCT02566265 ↗ |
| Known as | Fluzone High Dose Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02566265 ↗ |
| Modality | Vaccine | “tandem Fluzone High-Dose influenza vaccination” PMID 33683337 ↗ Mar 2021 |